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Aims: To describe hospitalizations of a cohort of patients with type 1 diabetes mellitus (T1DM) 
during 1973–1998 in the main complication groups by sex and T1DM lasting on average 9.5 
or 16.5 years.
Material and methods: The population (N = 5166) consisted of all Finnish patients with 
T1DM diagnosed before the age of 18 years between 1965–1979, derived from the Finnish 
population-based register of T1DM patients. Data on hospitalizations were obtained from the 
Finnish Hospital Discharge Register.
Results: In the early stages of T1DM, the majority of the use of hospitalizations was due to the 
treatment of T1DM without complications. Enormous increases were found for complications 
when diabetes lasted longer (from 9.5 to 16.5 years). For women, the yearly number of bed-days 
for renal complications increased 4.8-fold, for peripheral vascular disease 4.3-fold, and for 
ophthalmic complications 2.5-fold. For men, the corresponding increases were as follows: 5-fold, 
6.9-fold, and 2.5-fold. The yearly number of bed-days for nephropathy increased 7-fold. Bed-days 
for T1DM without complications dropped dramatically. The length of stay in hospitalizations 
decreased notably, but hospital visits increased when the duration of T1DM increased.
Conclusions: Hospitalizations due to complications substantially increase with aging of T1DM 
patients. Prevention of T1DM is strongly needed.
Keywords: T1DM, inpatient care, hospitalizations, complications
Introduction
Diabetes has major long-term implications, not only for the health and well-being 
of individuals, but also for health services costs.1 Diabetes may cause many 
complications, such as retinopathy, nephropathy, cardiac and cerebrovascular 
disease, and peripheral vascular disease with neuropathy, and the probability of 
developing these is related to the duration of diabetes and the metabolic control.2 
Diabetic ketoacidosis and severe hypoglycemia are acute complications that may 
be life-threatening.3 Patients with diabetes are also at increased risk for secondary 
complications, eg, influenza-associated respiratory illnesses.4 Inpatient hospital 
care is the major contributor to the health care costs of diabetes.5–9 In addition to 
glycosylated hemoglobin as a significant predictor of diabetes complications, urine 
albumin:creatine ratio, body mass index, triglycerides, and high-density lipoproteins 
are independent predictors of hospitalizations for complications due to diabetes.10 
Even a modest reduction in hospitalizations of people with diabetes could result 
in major savings;11 hospitalization data are crucial in developing strategies for 
preventing hospitalizations.12Risk Management and Healthcare Policy 2009:2 56
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As the burden of diabetes is increasing, it is vital to 
develop new prevention strategies and treatments. There 
have been several multicenter clinical trials designed to 
prevent type 1 diabetes mellitus (T1DM), which have tested 
nicotinamide, parenteral insulin, oral insulin, nasal insulin, 
and the elimination of cow’s milk from infant feeding.13 
These studies were aimed at preventing or delaying clinical 
T1DM, and have given certain hope that T1DM can be 
prevented, as new studies are emerging.13,14 Developing a 
vaccine for enterovirus is a new field of study, which looks 
promising in prevention of T1DM.14
In the studies conducted mainly in the United States, 
insulin analogs were noticed to offer a better balance 
between glycemic control and hypoglycemia when 
compared with human insulins, and the subsequent 
potential to reduce the costs of hospital treatments and 
chronic complications.15
In Finland, the incidence of T1DM is the highest in the 
world.16,17 Since the beginning of the 1990s, the incidence 
has increased, reaching 60 per 100,000 person-years in 
2005.18 The medical and financial burden of diabetes will 
increase on the Finnish society, on the health care sector 
and on affected persons, as the number of patients with 
severe complications may rise. The need for health eco-
nomic information, especially longitudinal, about T1DM 
will become more stressed.
In Finland, nationwide data on incident cases of 
childhood-onset diabetes exist since 1965.19 These data form 
a good basis for research into the epidemiology and health 
services utilization in patients with T1DM. The overall aim 
of this study was to describe the use of inpatient care of a 
cohort of childhood-onset diabetic patients prospectively 
during 1973 to 1998, especially in the main categories of 
diabetic complications.
Material and methods
The population consisted of all Finnish T1DM patients 
diagnosed before the age of 18 years between January 1st, 
1965 and December 31st, 1979 and derived from the Finnish 
population-based register with patients with T1DM. At the 
end of 1979, this dynamic cohort consisted of 5,166 patients 
(2,327 females, 2,839 males).
The Finnish population-based register belongs to the 
material of the Diabetes Epidemiology Research International 
(DERI) Study, which has been used in evaluating mortality 
in T1DM.20–22 The register was established by linking the 
Finnish Hospital Discharge Register (FHDR) with the Social 
Insurance Institution Central Drug Register using the unique 
personal identification numbers recorded in both registers. 
The Central Drug Registry only recorded the date of approval 
of the free-of-charge medication, so copies of the original 
certificates had been collected for the years 1965–1979 to 
obtain the actual dates of diagnosis.19 Data on hospitalizations 
were obtained from the FHDR.
Two cohorts were formed based on the duration of 
diabetes. The hospitalizations during two three-year 
periods of duration, 9–11 and 16–18 years, were compared 
in nine complication groups associated with diabetes.23 
The nine complication groups were the following: 
cerebrovascular disease, cardiac disease, peripheral vascular 
disease, neurological complications, renal complications, 
endocrine complications, ophthalmic complications, 
other complications, and coma. The complications and 
complication groups were based on the criteria of the 
American Diabetes Association.24 Cerebrovascular 
complications were extracted from neurological disorders. 
Diabetic coma was included as a separate group. The main 
diagnosis of each hospitalization was used in calculations. 
Hospitalizations in nine complication groups were 
compared between these two three-year periods (9–11 and 
16–18 years). Hospitalizations were first calculated for these 
three-year periods and then divided by three, indicating 
the effect of duration on hospitalizations when diabetes 
had lasted on average 9.5 years compared with 16.5 years. 
The amount of hospitalizations due to each complication 
group was compared with the amount of use due to all 
complications, hospitalizations due to other causes than 
diabetes, and hospitalizations due to all hospitalizations 
(due to any cause). Diabetes-related hospitalizations due 
to diabetic complications, and without complications 
(International Code of Diseases [ICD]: ICD-8 code 25000 
and ICD-9 code 2500B) were also calculated separately. The 
results were presented by ICD-9 codes, and ICD-8 codes 
were converted to correspond to ICD-9 codes, because the 
coding changed in 1987. ICD-10 was officially adopted on 
January 1st, 1996 in Finland (the first edition was published 
in 1995 and the second one in 1998). The ICD-10 codes 
for diabetes in FHDR changed markedly compared to the 
earlier versions (ICD-8 and ICD-9) and if this study could 
have used ICD-10 codes, another translation of the codes 
would have been needed, which would have complicated 
and biased the study too much.
The exact dates of death were used when calculating the 
number of patients alive (N1) in the beginning and at the end 
(N2) of the two periods, and then summed and divided by 
2 (N1+N2/2) in order to obtain the average number of people Risk Management and Healthcare Policy 2009:2 57
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alive during the two study periods. The average number of 
patients was 5,120 in the 9.5-year cohort and 5,010 in the 
16.5-year cohort. These figures were used in calculating 
bed-days and discharges per 1,000 patients.
The following principles were applied in calculations:
•  If there were two days or less between two treatment 
periods, they were defined as two different treatment 
periods if the main diagnoses of the periods were 
different. If the main diagnoses of the periods were the 
same, the periods were defined as one treatment period.
•  The days of admission to hospital and discharge from 
hospital were treated as a single bed-day.
•  Overlapping treatment periods of the same patient in two 
different locations were either errors or due to specific 
consultations and thus the overlapping part was omitted 
in order to avoid overestimation of bed-days.
•  Discharge (treatment period): Hospitalization period 
lasting for at least 15 hours.
•  Average length of stay (LOS): The number of hospital 
days divided by the number of treatment periods 
(discharges).
•  Bed-days per user: The number of bed-days divided by 
the number of patients who used hospital at least once 
during the period concerned.
•  As pregnancy is not a disease, hospitalizations due to 
pregnancies were omitted, eg, for comparison purposes 
(men/women).
Results
The mean age at diagnosis in the cohort was 10.3 years 
(standard deviation [SD] 4.4; min 0.7 and max 17.9). When 
the average duration of diabetes was 9.5 or 16.5 years, the 
mean ages of patients were 20 years (min 10; max 27.5) and 
27 years (min 17; max 34.5), respectively. Hospitalizations 
occurred between 1973–1998, follow-up being 26 years. The 
number of hospital users are shown in Table 1.
Bed-days for total population
In the 9.5-year cohort, the shares of bed-days of other 
complications, ophthalmic complications, renal complications 
and coma were the biggest, and their shares of the total amount 
of bed-days were 6.0%, 3.6%, 2.2%, and 1.5%, respectively.
In the 16.5-year cohort other, renal, ophthalmic and 
peripheral vascular complications constituted the biggest shares 
of the amount of bed-days of all complications. Especially 
renal, but also peripheral vascular and cardiovascular 
complications showed the biggest increases in shares 
compared with the 9.5-year cohort, while the shares of other 
complications and coma dropped clearly. The shares of other, 
renal, ophthalmic and peripheral vascular complications of 
the total amount of bed-days were 15.0%, 12.1%, 11.3%, and 
3.0%, respectively. The share of the first four complication 
groups combined (cerebrovascular, cardiovascular, peripheral 
vascular, and neurological complications) increased from 
1.3% to 5.5%.
Table 1 number of hospital users during the periods of three years by sex and duration of diabetes (by complication groups, complications 
combined,   T1DM without complications and total number)
No. of females No. of males No. of females No. of males
T1DM T1DM T1DM T1DM T1DM T1DM
9–11 yrs. 9–11 yrs. 16–18 yrs. 16–18 yrs. 9–11 yrs. 16–18 yrs.
ceRVAsc 3 2 7 3 5 10
cARVAsc 2 7 8 15 9 23
PeRVAsc 11 12 60 53 23 113
neUROL 11 18 32 25 29 57
RenAL 47 33 173 107 80 280
enDOcRin 0 0 0 1 0 1
OPHTHALMic 104 77 271 230 181 501
OTHeR complicat. 112 122 166 164 234 330
cOMA 45 38 18 32 83 50
Complications 
total
295 274 555 495 569 1050
2500B/25000 1106 1042 469 457 2148 926
TOTAL use 1349 1378 1213 1171 2727 2384
Abbreviations: cervasc, cerebrovascular disease; carvasc, cardiac disease; pervasc, peripheral vascular disease; neurol, neurological complications; renal, renal complications; 
endocrine, endocrine complications; ophthalmic, ophthalmic complications; 2500B/25000, T1DM without complications (icD-9/icD-8 codes).Risk Management and Healthcare Policy 2009:2 58
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The total yearly number of bed-days used due to 
complications during the first and second three-year periods 
increased from 6,742 to 18,158 days, while the number of 
bed-days used due to any cause decreased from 45,986 to 
40,669 days. The share of the bed-days of the nine complica-
tion groups of the total amount of bed-days rose from 14.7% 
to 44.6%. The number of bed-days due to diabetes without 
complications dropped by 73%.
As calculated by the mean numbers of yearly bed-days 
per 1,000 patients by the complication group and the dura-
tion of diabetes, other complications remained the biggest 
complication group when the duration of diabetes increased, 
while renal diseases replaced ophthalmic diseases as the 
second biggest group. Hospitalizations due to cardiovascular 
(+1,406%), peripheral vascular (+474%), renal (+387%), 
ophthalmic (+185%), cerebrovascular (+131%), other 
(+126%) and neurological (+52%) complications increased. 
Endocrine complications were practically nonexistent. Bed-
days due to coma decreased by 54%.
Bed-days by sex
Female patients had a bigger share of bed-days due to 
ophthalmic complications than men while male patients had 
a bigger share due to other complications in the 9.5-year 
cohort (Figure 1). In the 16.5-year cohort female patients 
had a bigger share of bed-days due to renal complications 
while male patients had a bigger share due to peripheral com-
plications. The biggest change in the shares of bed-days of 
any complication group was the increases in shares of renal 
complications in both sexes.
Female patients used more bed-days per 1,000 patient-
years than males; in the 9.5-year cohort for all hospitaliza-
tions 39% more and in the 16.5-year cohort 32% more than 
males, and for hospitalizations due to complications 32% 
and 30% more, respectively. Female patients had used 
almost twice more bed-days (per 1,000 patient-years) due to 
ophthalmic complications than males in the 9.5-year cohort 
and 47% more in the 16.5-year cohort, and 60% more yearly 
bed-days due to renal complications in the 9.5-year cohort 
and 55% more in the 16.5-year cohort. Male patients had 
used 52% more yearly bed-days due to peripheral vascular 
complications when diabetes lasted longer. The number of 
bed-days due to coma dropped more in female than male 
patients.
There were marked increases in the yearly number of 
bed-days due to certain complications when diabetes had 
lasted longer. From the 9.5-year cohort to the 16.5-year 
cohort, the number of bed-days due to renal complications 
increased 4.8-fold, peripheral vascular complications 
4.3-fold, neurological complications 3.2-fold, ophthalmic 
complications 2.5-fold, and other complications 2.3-fold in 
female patients. In male patients, the number of bed-days due 
to peripheral vascular complications increased 6.9-fold, renal 
complications 5-fold, ophthalmic complications 3.4-fold, and 
other complications 2.2-fold.
Length of stay
In all complication groups combined there was a drop in 
average length of stay (LOS) from 7.7 (SD 8.1) to 6.9 days 
(SD 9.2), and LOS for total inpatient care (for any cause) 
dropped from 7.4 (SD 10.3) to 6.4 days (SD 19.2), as the 
duration of diabetes increased by seven years. Generally, 
male patients seemed to have stayed slightly longer in 
hospital during their treatment periods than females. Among 
both sexes, LOS for many complications seemed to decrease, 
and LOS due to ophthalmic complications and coma had a 
clear drop among both sexes (1.7 to 1.9 days), as did LOS 
due to renal complications among female patients (8.9 to 
7.1 days). LOS due to cardiovascular complications increased 





















% of bed-days, T1DM 9.5 years, females
% of bed-days, T1DM 16.5 years, females
% of bed-days, T1DM 9.5 years, males
% of bed-days, T1DM 16.5 years, males
Figure 1 Percentages of yearly bed-days due to complications out of all bed-days due to 
complications by complication group, duration of type 1 diabetes (TiDM) and sex.
Abbreviations: cervasc, cerebrovascular disease; carvasc, cardiac disease; 
Pervasc, Peripheral vascular disease; neurol, neurological complications; renal, renal 
complications; endocrin, endocrin complications; ophthalmic, ophthalmic complications; 
other, other complications.Risk Management and Healthcare Policy 2009:2 59
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increased in women, but decreased in men. The number of 
patients in these two groups however was small.
Most common diagnoses
Regarding total inpatient care, diabetes without complications 
was a dominating diagnosis when diabetes had lasted 
9–11 years, representing 61% of all bed-days and 71% of 
bed-days due to other causes than complications (Table 2). 
The number of bed-days due to the treatment of diabetes 
without complications was 4.2-fold that due to the treatment 
of complications when diabetes had lasted 9–11 years. 
Its share dropped by 73%, when the duration of diabetes 
increased by seven years. The number of bed-days for treating 
diabetic nephropathy showed a seven-fold rise when the 
duration of diabetes increased.
The number of bed-days for treating all other defined 
complications, ophthalmic complications and retinopathy 
increased over 3-fold, while the number of bed-days for 
treating nondefined complications decreased 63% when 
diabetes lasted longer.
Treatment of mental diseases and disorders (eg, various 
personality disorders, schizophrenia, and depression) seemed 
to cause a large number of bed-days and long treatment peri-
ods. Measured by the number of bed-days and discharges, 
ketoacidosis, diabetic microangiopathy, diabetic neuropathy, 
and coma were among the most common diagnoses in the 
cohort with a longer duration of diabetes. The changes in the 
number of bed-days during the two three-year periods relating 
to certain diagnoses of ophthalmic complications turned out 
to be interesting. The number of bed-days due to treatment 
of glaucoma was 8-fold and that due to treatment of diabetic 
retinopathy 2.7-fold in the 16.5-year cohort compared with 
the 9.5-year cohort.
Discussion
Drug treatment for diabetes is free of charge in Finland. 
Patients receive reimbursement from the Social Insurance 
Institution after the institution has approved the application 
based on a certificate from the physician. Only occasionally 
the parents of a diabetic child fail to seek reimbursement for 
insulin costs, and the child is not included in the nationwide 
Central Drug Registry. The ascertainment rate of childhood 
diabetes is almost 100%;19 the case ascertainment in this 
cohort was virtually complete.19,25
In Finland, there are better possibilities to conduct 
register-based health studies than in most other countries, as 
the coverage of registers is good and their quality for research 
purposes is excellent. It is possible to link registers with a 
personal identification code.26 The accuracy and quality of 
the FHDR data for epidemiological research purposes have 
been estimated.26–31 In a comparison of coded diagnoses with 
hospital records during the corresponding hospital stay, 95% 
of the main diagnoses and 96% of the dates of admission and 
discharge were correct in 1986.
The main diagnoses of hospital discharges were 
compared. Thus, the inferior accuracy of the secondary 
diagnoses in FHDR had no relevance. The use of primary 
diagnosis also prevented double counting, that can happen 
when multiple diagnoses are used.
Hospitalizations after diabetes durations of 9–11 and 
16–18 years were compared. The hospitalizations were first 
considered in three-year periods to obtain steadier frequencies 
across years and to damp fluctuations. These three-year 
numbers were divided by three to get yearly figures and to 
demonstrate how hospital use differs in complication groups 
when diabetes has lasted on average 9.5 years compared 
with 16.5 years. Yearly inpatient care was calculated per 
1,000 patients to adjust for different numbers of men and 
women and to take into account mortality.
Ketoacidosis and hypoglycemia have ICD-9 codes, but 
not ICD-8 codes. Their inclusion in complication grouping 
would have distorted the comparisons so they were excluded 
from the main groupings. Physicians in hospital may have 
coded these into secondary diagnoses, or most likely into 
group other complications (diabetes with other specified/
unspecified complications; Table 2). This is supported by the 
fact, that besides the number of bed-days, number of hospital 
users also clearly increased in that group (Table 1).
The lack of ICD-8 codes for microangiopathy may have 
caused an underestimation of peripheral vascular complica-
tions in the younger group, and an overestimation of the 
growth as diabetes lasted longer.
No hospital periods exceeding 365 days existed in hospi-
tal use for any complication group during the two three-year 
observation periods; very long hospital periods (“outliers”) 
did not affect the results. Only a few shorter outliers were 
observed, which raised the means of bed-days in certain 
groups and observation periods.
Hospital use due to complications increased markedly; 
the numbers of hospital users doubled, the annual number 
of discharges increased 3-fold and that of bed-days 2.8-fold 
when diabetes lasted longer.
With increasing duration of diabetes, the length of 
stay decreased in all complication groups, except in 
cerebrovascular, cardiovascular, and peripheral vascular 
complications. Although the LOS in hospital generally Risk Management and Healthcare Policy 2009:2 60
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Table 2 number of bed-days and discharges, and mean length of stay (LOs) of diseases (by diagnoses) causing most inpatient care in 
complication groups (ranked by the amount of bed-days) and for total use in the two observation period of three years of T1DM duration
T1DM duration 9–11 years T1DM duration 16–18 years
Bed-days Discharges LOS Diagnosis Bed-days Discharges LOS Diagnosis
Total hospital use
28045 3856 7.3 Diabetes without 
complications
7711 1539 5.0 Diabetes without 
complications
1801 229 7.9 Diabetes with other specified 
complications
5707 644 8.9 Diabetes with other specified 
complications
1345 185 7.3 Diabetes with ophthalmic 
complications + retinopathy
4262 537 7.9 Diabetic nephropathy
1048 20 52.4 Anxiety dissociative and 
somatoform disorders
4012 756 5.3 Diabetes with ophthalmic 
complications + retinopathy
749 76 9.9 Diabetes with unspecified 
complication
1978 6 329.7 schizophrenic disorders
696 106 6.6 Diabetes with hyperosmolarity 1310 43 30.5 Personality disorders
643 9 71.4 schizophrenic disorders 609 141 4.3 Diabetes with ketoacidosis
609 74 8.2 Diabetic nephropathy 551 111 5.0 Microangiopathy
602 15 40.1 Personality disorders 431 25 17.2 Multiple sclerosis
347 72 4.8 Diabetes with ketoacidosis 385 59 6.5 Diabetic neuropathy
345 4 86.3 episodic mood disorders 317 13 24.4 Rheumatoid arthritis 
specified
312 65 4.8 Diabetes with 
hyperosmolarity
Cerebrovascular complications
30 1 30.0 cerebral embolism 96 5 19.2 cerebral thrombosis
19 2 9.5 Transient cerebral ischemia 38 1 38.0 Other cerebrovascular 
disorders
16 1 16.0 intracerebral hemorrhage 13 3 4.3 Transient ischemic attack
Cardiovascular complications
8 3 2.7 Atrial fibrillation 133 13 10.2 Acute myocardial infarction
7 2 3.5 Old myocardial infarction 75 2 37.5 congestive heart failure
4 3 1.3 Other specified cardiac 
dysrhythmias
72 8 9.0 Old myocardial infarction
24 2 12.0 congestive heart failure/
pulmonary edema
31 2 15.5 Unstable angina pectoris
Peripheral vascular complications
90 11 8.2 Microangiopathy 547 109 5.0 Microangiopathy
58 7 8.3 chronic ulcer of other 
specified/unspecified sites
142 9 15.8 chronic ulcer in other 
specified/unspecified sites
23 3 7.7 Traumatic amputation of 
thumb complicated
117 7 16.7 chronic ulcer
16 1 16.0 Peripheral vascular disease 
unspecified
73 10 7.3 Diabetic gangrene
16 2 8.0 Phlebitis and thrombophlebitis 70 5 14.0 Ulcer in lower leg
Neurological complications
273 36 7.6 Diabetic neuropathy 385 59 6.5 Diabetic neuropathy
28 20 1.4 carpal tunnel syndrome
10 4 2.5 Peripheral nerve disorder 
Median nerve
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decreased, the number of discharges per user increased, 
especially for other, renal, and ophthalmic complications; 
patients were more frequently in hospital. The number of bed-
days per user for complication groups increased because the 
drop of the LOS was offset by the increase in the frequency 
of hospital visits. More patients without complications may 
have been treated in outpatient care and at home as a result of 
a change in treatment practices and a rise in patients’ age.
Generally, women used clearly more inpatient treat-
ment than men. One explanation may be that women seek 
health care more readily than men, which has been reported 
earlier.32,33 Men’s attitudes towards diseases and symptoms 
are different compared with those of women’s, which may 
lead to men’s slower reaction to seek health care.34
As diabetes lasted longer, men had a slightly bigger 
increase than women in the hospital use due to all com-
plications and in the total hospital use, as measured by the 
number of discharges, and in the hospital use due to all 
complications, as measured by the number of bed-days. 
Women’s total number of bed-days dropped slightly more 
than that of men. Women visited hospitals slightly more 
frequently than men, when total hospital use and hospital 
use due to other causes than diabetes were observed. Men 
generally stayed during their treatment periods a bit longer 
in hospital than women, especially considering the group of 
complications combined, other hospitalizations than those 
due to diabetes and total hospitalizations, when diabetes 
had lasted 9.5 years or 16.5 years; the LOS decreased for 
Table 2 (Continued)
T1DM duration 9–11 years T1DM duration 16–18 years
Bed-days Discharges LOS Diagnosis Bed-days Discharges LOS Diagnosis
Renal complications
609 74 8.2 Diabetic nephropathy 4262 537 7.9 Diabetic nephropathy
199 19 10.5 Renal infection/Acute  
pyelonephritis
301 54 5.6 Renal infection.   Acute 
pyelonephritis
124 9 13.8 Renal infection/chronic  
pyelonephritis
164 14 11.7 Other disease of urinary 
tract
27 4 6.8 Renal infection unspecified 64 6 10.7 Renal infection. chronic 
pyelonephritis
26 2 13.0 Acute nephritis 43 8 5.4 chronic nephritis with 
uremia
Endocrine complications
– – – – 3 1 3.0 Hyperkalemia
Ophthalmic complications
1174 153 7.7 Diabetic retinopathy 3143 566 5.6 Diabetic retinopathy
171 32 5.3 Diabetes with ophthalmic 
complications
739 174 4.2 Diabetes with ophthalmic 
complications
93 12 7.8 Diabetic cataract 250 50 5.0 glaucoma
41 9 4.6 Acute iridocyclitis 137 27 5.1 Diabetic cataract
66 9 7.3 cataract 95 6 15.8 Diabetes with other specified 
ophthalmic complications
31 8 3.9 glaucoma 80 22 3.6 cataract
27 3 9.0 iridocyclitis chronic uveitis 72 10 7.2 Hemorrhage of vitreous 
body
Other complications
1640 230 7.1 Diabetes with other specified 
complications
5689 642 8.9 Diabetes with other specified 
complications
872 78 11.2 Diabetes with unspecified 
complications
277 57 4.9 Diabetes with unspecified 
complications
115 13 8.8 cellulitis. cutaneous/ 
subcutaneous infections
66 6 11.0 chronic osteomyelitis
77 3 25.7 chronic osteomyelitis 17 4 4.3 cellulitis. cutaneous/
subcutaneous infectionsRisk Management and Healthcare Policy 2009:2 62
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both sexes by about the same amount. The yearly numbers 
of bed-days and discharges per user considering all 
complications combined increased for both sexes clearly 
as the duration increased.
An increase in the proportion of yearly discharges due to 
renal complications was notably bigger for women than for 
men as the duration of diabetes increased, but for ophthalmic 
complications, men had a clearly bigger increase. The sex 
difference in yearly discharges was about the same in the 
9.5-year cohort for ophthalmic complications as in the 
16.5-year cohort for renal complications. Thus, women used 
hospital relatively more frequently due to ophthalmic causes 
than men when diabetes had lasted on average 9.5 years, 
but they visited hospital relatively more often for renal 
causes than men when the duration increased. The biggest 
differences between the sexes in the absolute number of 
discharges per 1,000 patients per year were that women 
had twice as much ophthalmic and over 50% more renal 
complication discharges when diabetes had lasted 9.5 years, 
and almost 40% more ophthalmic and twice as much renal 
complication discharges compared with men, when diabetes 
lasted longer.
In both sexes, the share of renal complications showed 
a considerable increase, replacing ophthalmic ones as the 
second biggest group with the increased duration. The share 
of yearly bed-days of ophthalmic complications dropped in 
women but rose in men. Women used clearly more bed-days 
for ophthalmic causes than men when diabetes had lasted on 
average 9.5 years, but the difference leveled off when diabetes 
lasted longer. The most striking sex differences considering 
the absolute number of yearly bed-days per 1,000 patients 
were that women had twice as many ophthalmic and 60% 
more renal complication discharges when diabetes had 
lasted 9.5 years, and around 50% more ophthalmic and renal 
complication bed-days compared to men when diabetes had 
lasted longer.
In terms of bed-days and discharges, men had a higher 
proportion in the complication group “other” than women 
also as the duration increased. This suggests that men 
were more prone to be given diagnoses “other defined” or 
“nondefined” complications and exact diagnoses were for 
some reason more seldom for men than for women.
There were vast increases in the yearly numbers of 
bed-days due to certain complications as the duration 
increased. These stress the importance of good metabolic 
control and management.
Hospitalizations due to endocrine complications was 
practically nonexistent. The small numbers of cerebrovascular 
bed-days was surprising. These complications possibly 
evolve later, and should be examined in longer periods 
of durations of T1DM, than this study gave possibilities 
(although the follow-up period was 26 years).
The number of bed-days due to neurological complications 
increased in women, but decreased in men, as the duration 
of diabetes increased. That is partly explained by the fact 
that the number of female users increased 3-fold while the 
number of male users increased by 40%.
The occurrence of infectious complications might seem 
low. We studied hospitalizations, and many patients with 
infectious complications are treated as outpatients. This 
is the main reason for the low occurrence of infectious 
complications.
Also, infectious complications were spread among certain 
complication groups: renal complications (renal infections), 
peripheral vascular complications (microangiopathy, 
chronic ulcers etc.), and other complications. We did not 
want to present infections as an own group (as the grouping 
was mainly based on the criteria by American Diabetes 
Association).
The study has some limitations. No nondiabetic control 
group was used. Using a control group could have allowed 
the incremental effect of diabetes on hospitalizations to 
be shown. Due to difficulties in obtaining a valid and 
reliable control group, and due to limited resources and the 
scope of the study, the use of a control group was omitted. 
The primary diagnosis of hospital use was used to avoid 
double counting. This may have caused an underestimation 
of hospitalizations, as diabetes is often a contributory cause 
and is marked as a secondary diagnosis in hospital records, 
and they are not systematically recorded. This study was 
population-based, as the study population consisted of 
all Finnish patients with T1DM diagnosed before the age 
of 18 years (between 1965–1979). The study type was 
designed to be descriptive, not predictive or explanatory, 
and the main objective was to describe how hospital use 
changed during a long follow-up period. The data were 
formed by linking registers. The register data included only 
few variables about the population, and the possibilities 
to perform multivariate analyses to control possible 
confounding variables were small. This is why statistical 
modeling was not used.
For decision makers, especially in health care, it is 
important to know how diseases, eg, diabetes and its 
complications evolve as the duration increases in a long 
run, to help allocating resources in planning health care. 
We believe that this study gives more information, eg, for Risk Management and Healthcare Policy 2009:2 63
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that purpose, as studies similar to this are extremely rare, 
practically nonexistent, especially by sex.
Conclusions
As the duration of T1DM increased from 9.5 to 16.5 years 
on average, the yearly numbers of bed-days due to all 
complications of diabetes almost tripled, while the yearly 
numbers of bed-days due to diabetes without complications 
dropped considerably. The numbers of bed-days due to renal 
complications, peripheral vascular diseases, and ophthalmic 
complications increased markedly. Women consumed 
clearly more bed-days than men, especially due to renal and 
ophthalmic complications. By preventing and delaying com-
plications, some resources devoted to treating persons with 
diabetes might be allocated to treatment of other diseases, 
or other purposes. Additionally, extra life-years and quality 
of life gains should be achieved.
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